Soccermom
06-15-2009, 09:37 AM
<TABLE class=forumline border=0 cellSpacing=0 cellPadding=0 width="100%"><TBODY><TR><TD class=subjecttable vAlign=top width="100%" align=left><TABLE class=subjecttable border=0 cellSpacing=0 cellPadding=0 width="100%"><TBODY><TR><TD class=row1_message colSpan=3 align=left>Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers.
Sub-category: Adjuvant Therapy
Category: Breast Cancer--Local-Regional and Adjuvant Therapy
Meeting: 2009 ASCO Annual Meeting
Citation: J Clin Oncol 27:15s, 2009 (suppl; abstr 549)
Abstract No: 549
Attend this session at the ASCO Annual Meeting!
Session: Breast Cancer - Local-Regional and Adjuvant Therapy
Type: General Poster Session
Time: Monday June 1, 1:00 PM to 5:00 PM
Location: Level 2, West Hall C
Personalize your Annual Meeting experience with a suggested or customized itinerary!
Author(s): S. Shak, G. Palmer, F. L. Baehner, C. Millward, D. Watson, G. W. Sledge; Genomic Health, Redwood City, CA; Indiana University School of Medicine, Indianapolis, IN
Abstract:
Background: Because male breast cancer (BC) is rare, there is little known about the disease and treatment is extrapolated from female BC. Newer molecular technologies have not been used to profile male BC. We report here a study of quantitative gene expression by gender status in tumor specimens submitted for Recurrence Score testing. Methods: All estrogen receptor positive tumor specimens successfully examined in the Genomic Health laboratory from June 2004 through December 2008 were included. Quantitative expression for each gene was measured by the 21 gene oncotype DX assay on a scale from 0 to 15 (relative to reference genes), where a one unit increment is associated with a 2-fold change in expression. Results: There were 347 male and 82,434 female BCs. The males were older (mean age 63.8 vs 57.4 yrs). Standard histopathology was similar, although slightly more male BCs were ductal (83% vs 78%). Like female BC, there was a wide variation in gene expression in male BC. The distribution of RS in males and females was similar - RS mean (±SD) 18.1 (±11.2) in males and 19.1 (±10.2) in females (p = NS). The proportion of tumors with RS <18, 18 - 30, and ≥ 31 was 53.6%, 35.2%, and 11.2% in males and 53.4%, 36.3%, and 10.3% in females. Although the patterns of expression of the Oncotype DX genes were more similar than different in males and females some differences were notable. Mean expression of ER, PR, and SCUBE2 were 0.5 units higher in males. Mean expression of the proliferation genes, Ki-67, MYBL2, Survivin, Cyclin B1, and STK15, were 0.5 units higher in males. Mean expression of STMY3 was 0.9 units higher in males. Of note, whereas the level of quantitative ER significantly increased with increasing patient age in females (0.4 units per decade), little increase was observed in males (<0.1 units per decade). Conclusions: This large genomic study of male BC reveals a heterogeneous biology as measured by the standardized quantitative oncotype DX breast cancer assay, similar to that observed in female BC. Some differences, which may reflect the differences in hormone biology between males and females, were noted and deserve further study.
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Other Abstracts in this Sub-Category:
1. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.
Meeting:2009 ASCO Annual Meeting Abstract No: CRA501 First Author: A. Tutt
Category:Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
2. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
Meeting:2009 ASCO Annual Meeting Abstract No: 502 First Author: J. Gronwald
Category:Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
3. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study.
Meeting:2009 ASCO Annual Meeting Abstract No: CRA509 First Author: V. Dezentje
Category:Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
More...
</TD></TR></TBODY></TABLE></TD></TR><TR height=3><TD class=spacerrow_taller colSpan=3></TD></TR><TR align=middle><TD class=catBottom height=28 colSpan=3><TABLE border=0 cellSpacing=0 cellPadding=0><TBODY><TR><FORM method=post action=viewtopic.php?t=32011&start=0></FORM></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>
Sub-category: Adjuvant Therapy
Category: Breast Cancer--Local-Regional and Adjuvant Therapy
Meeting: 2009 ASCO Annual Meeting
Citation: J Clin Oncol 27:15s, 2009 (suppl; abstr 549)
Abstract No: 549
Attend this session at the ASCO Annual Meeting!
Session: Breast Cancer - Local-Regional and Adjuvant Therapy
Type: General Poster Session
Time: Monday June 1, 1:00 PM to 5:00 PM
Location: Level 2, West Hall C
Personalize your Annual Meeting experience with a suggested or customized itinerary!
Author(s): S. Shak, G. Palmer, F. L. Baehner, C. Millward, D. Watson, G. W. Sledge; Genomic Health, Redwood City, CA; Indiana University School of Medicine, Indianapolis, IN
Abstract:
Background: Because male breast cancer (BC) is rare, there is little known about the disease and treatment is extrapolated from female BC. Newer molecular technologies have not been used to profile male BC. We report here a study of quantitative gene expression by gender status in tumor specimens submitted for Recurrence Score testing. Methods: All estrogen receptor positive tumor specimens successfully examined in the Genomic Health laboratory from June 2004 through December 2008 were included. Quantitative expression for each gene was measured by the 21 gene oncotype DX assay on a scale from 0 to 15 (relative to reference genes), where a one unit increment is associated with a 2-fold change in expression. Results: There were 347 male and 82,434 female BCs. The males were older (mean age 63.8 vs 57.4 yrs). Standard histopathology was similar, although slightly more male BCs were ductal (83% vs 78%). Like female BC, there was a wide variation in gene expression in male BC. The distribution of RS in males and females was similar - RS mean (±SD) 18.1 (±11.2) in males and 19.1 (±10.2) in females (p = NS). The proportion of tumors with RS <18, 18 - 30, and ≥ 31 was 53.6%, 35.2%, and 11.2% in males and 53.4%, 36.3%, and 10.3% in females. Although the patterns of expression of the Oncotype DX genes were more similar than different in males and females some differences were notable. Mean expression of ER, PR, and SCUBE2 were 0.5 units higher in males. Mean expression of the proliferation genes, Ki-67, MYBL2, Survivin, Cyclin B1, and STK15, were 0.5 units higher in males. Mean expression of STMY3 was 0.9 units higher in males. Of note, whereas the level of quantitative ER significantly increased with increasing patient age in females (0.4 units per decade), little increase was observed in males (<0.1 units per decade). Conclusions: This large genomic study of male BC reveals a heterogeneous biology as measured by the standardized quantitative oncotype DX breast cancer assay, similar to that observed in female BC. Some differences, which may reflect the differences in hormone biology between males and females, were noted and deserve further study.
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Other Abstracts in this Sub-Category:
1. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer.
Meeting:2009 ASCO Annual Meeting Abstract No: CRA501 First Author: A. Tutt
Category:Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
2. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.
Meeting:2009 ASCO Annual Meeting Abstract No: 502 First Author: J. Gronwald
Category:Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
3. Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study.
Meeting:2009 ASCO Annual Meeting Abstract No: CRA509 First Author: V. Dezentje
Category:Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
More...
</TD></TR></TBODY></TABLE></TD></TR><TR height=3><TD class=spacerrow_taller colSpan=3></TD></TR><TR align=middle><TD class=catBottom height=28 colSpan=3><TABLE border=0 cellSpacing=0 cellPadding=0><TBODY><TR><FORM method=post action=viewtopic.php?t=32011&start=0></FORM></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>